Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1987 Oct;25(10):1920–1925. doi: 10.1128/jcm.25.10.1920-1925.1987

Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination.

R N Jones 1, A L Barry 1
PMCID: PMC269368  PMID: 3117843

Abstract

The ampicillin-sulbactam combination was evaluated in vitro to determine the optimal susceptibility testing conditions among five combination ratios and four fixed concentrations of sulbactam. The organisms tested were markedly resistant to aminopenicillins and most other beta-lactams. The ratio of 2:1 is recommended to assure recognition of the ampicillin-sulbactam spectrum and minimize false-susceptible results among strains known to be resistant to this combination. Proposed MIC breakpoint concentrations were compatible with levels in serum achieved with recommended clinical doses. Cross-resistance analyses comparing ampicillin-sulbactam and amoxicillin-clavulanate showed comparable activity and spectra. However, the major interpretive disagreement was sufficient to require separate testing of these aminopenicillin-inhibitor combinations. The recommended ampicillin-sulbactam MIC susceptibility breakpoints are as follows: (i) less than or equal to 8.0/4.0 micrograms/ml for tests against members of the family Enterobacteriaceae, anaerobes, nonenteric gram-negative bacilli, staphylococci, Haemophilus influenzae, and Branhamella catarrhalis; (ii) the ampicillin MICs alone interpreted by National Committee for Clinical Laboratory Standards criteria should predict ampicillin-sulbactam susceptibility for the enterococci, streptococci, and Listeria monocytogenes. MIC quality control ranges were determined by multiple laboratory broth microdilution trials for the ampicillin-sulbactam 1:1 and 2:1 ratio tests.

Full text

PDF
1920

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C., Jacobs M. R., Spangler S. K., Yamabe S. Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes. Antimicrob Agents Chemother. 1986 Nov;30(5):789–791. doi: 10.1128/aac.30.5.789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aswapokee N., Neu H. C. A sulfone beta-lactam compound which acts as a beta-lactamase inhibitor. J Antibiot (Tokyo) 1978 Dec;31(12):1238–1244. doi: 10.7164/antibiotics.31.1238. [DOI] [PubMed] [Google Scholar]
  3. Barry A. L., Gavan T. L., Jones R. N., Ayers L. W., Fuchs P. C., Gerlach E. H., Thornsberry C. Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid. Diagn Microbiol Infect Dis. 1987 May;7(1):83–87. doi: 10.1016/0732-8893(87)90076-9. [DOI] [PubMed] [Google Scholar]
  4. Barry A. L., Jones R. N., Thornsberry C. Interpretive standards and quality control limits for susceptibility tests with ampicillin-sulbactam combination disks. J Clin Microbiol. 1984 Feb;19(2):134–139. doi: 10.1128/jcm.19.2.134-139.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brown R. M., Wise R., Andrews J. M., Hancox J. Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother. 1982 Apr;21(4):565–567. doi: 10.1128/aac.21.4.565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. English A. R., Girard D., Cimochowski C., Faiella J., Retsema J. A., Lynch J. E. Activity of sulbactam/ampicillin in screening and discriminative animal models of infection. Rev Infect Dis. 1986 Nov-Dec;8 (Suppl 5):S535–S542. doi: 10.1093/clinids/8.supplement_5.s535. [DOI] [PubMed] [Google Scholar]
  7. English A. R., Retsema J. A., Girard A. E., Lynch J. E., Barth W. E. CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization. Antimicrob Agents Chemother. 1978 Sep;14(3):414–419. doi: 10.1128/aac.14.3.414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Foulds G. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev Infect Dis. 1986 Nov-Dec;8 (Suppl 5):S503–S511. doi: 10.1093/clinids/8.supplement_5.503. [DOI] [PubMed] [Google Scholar]
  9. Fuchs P. C., Barry A. L., Thornsberry C., Gavan T. L., Jones R. N. In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limits. Antimicrob Agents Chemother. 1983 Jul;24(1):31–38. doi: 10.1128/aac.24.1.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hartman B. J., Tomasz A. Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. J Bacteriol. 1984 May;158(2):513–516. doi: 10.1128/jb.158.2.513-516.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lees L., Milson J. A., Knirsch A. K., Greenhalgh K. Sulbactam plus ampicillin: interim review of efficacy and safety for therapeutic and prophylactic use. Rev Infect Dis. 1986 Nov-Dec;8 (Suppl 5):S644–S650. doi: 10.1093/clinids/8.supplement_5.s644. [DOI] [PubMed] [Google Scholar]
  12. Retsema J. A., English A. R., Girard A. E. CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides. Antimicrob Agents Chemother. 1980 Apr;17(4):615–622. doi: 10.1128/aac.17.4.615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Retsema J. A., English A. R., Girard A., Lynch J. E., Anderson M., Brennan L., Cimochowski C., Faiella J., Norcia W., Sawyer P. Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection. Rev Infect Dis. 1986 Nov-Dec;8 (Suppl 5):S528–S534. doi: 10.1093/clinids/8.supplement_5.s528. [DOI] [PubMed] [Google Scholar]
  14. Roy C., Foz A., Segura C., Tirado M., Fuster C., Reig R. Plasmid-determined beta-lactamases identified in a group of 204 ampicillin-resistant Enterobacteriaceae. J Antimicrob Chemother. 1983 Nov;12(5):507–510. doi: 10.1093/jac/12.5.507. [DOI] [PubMed] [Google Scholar]
  15. Washburn R. G., Durack D. T. Efficacy of ampicillin plus a beta-lactamase inhibitor (CP-45,899) in experimental endocarditis due to Staphylococcus aureus. J Infect Dis. 1981 Sep;144(3):237–243. doi: 10.1093/infdis/144.3.237. [DOI] [PubMed] [Google Scholar]
  16. Wexler H. M., Harris B., Carter W. T., Finegold S. M. In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria. Antimicrob Agents Chemother. 1985 May;27(5):876–878. doi: 10.1128/aac.27.5.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wise R., Andrews J. M., Bedford K. A. Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins. J Antimicrob Chemother. 1980 Mar;6(2):197–206. doi: 10.1093/jac/6.2.197. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES